Wen Chuan Zhou
Vorstandsvorsitzender bei MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
Vermögen: 726 590 $ am 31.05.2024
Aktive Positionen von Wen Chuan Zhou
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Direktor/Vorstandsmitglied | 01.01.2009 | - |
| Vorstandsvorsitzender | 01.01.2009 | - | |
| GONGNIU GROUP CO.,LTD. | Direktor/Vorstandsmitglied | 20.05.2021 | - |
Shenzhen Wingor Bio-technology Co., Ltd.
 Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Wen Chuan Zhou
Ausbildung von Wen Chuan Zhou
| University of British Columbia | Graduate Degree |
| The Chinese University of Hong Kong | Masters Business Admin |
Statistik
International
| Hong Kong | 3 |
| China | 3 |
| Kanada | 2 |
Operativ
| Director/Board Member | 3 |
| Chief Executive Officer | 1 |
| Masters Business Admin | 1 |
Sektoral
| Consumer Services | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Distribution Services |
| GONGNIU GROUP CO.,LTD. | Producer Manufacturing |
| Private Unternehmen | 1 |
|---|---|
Shenzhen Wingor Bio-technology Co., Ltd.
Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Commercial Services |
- Börse
- Insiders
- Wen Chuan Zhou
- Erfahrung